Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is a good setup. Sellers are clearly getting exhausted now. Bodes well for a nice technical bounce. I think near term upside resistance might be around that $60 level. Some of the gap is going to get filled. If they release something positive, short covering will easily break through that upside technical resistance level bringing $75 to $80 back in play. Either way looks a very comfortable swing from such depressed levels imho. God bless and have a great day all!
jondoeuk,
Since you hold prof. Stupp in high esteem, the following papers from Dr. Stupp might interest you. The papers are sent to the peer-review journals between 2021 and 2023. For each paper, read the conflict of interest part to see to which company Dr. Stupp provided consulting service. Don't tell us that this doesn't mean anything.
https://www.jci.org/articles/view/163447
https://www.nature.com/articles/s41591-023-02347-y
https://aacrjournals.org/clincancerres/article/28/1/129/675012/Temporal-Muscle-Thickness-as-a-Prognostic-Marker
Also, jondoeuk, all your anti-NWBO nonsense you posting won't help NVCR at all, as the microwave frequency has a very, very, very limited additive utility & oncologists/patients have becoming increasingly aware of that fact IMO..
Just go read the response of a patients referenced on the moonshot meeting who stop using it and had a very negative opinion about it...
Think we climb back to low to mid $50’s before weeks end. Test $60 soon after. Staying the course. Have a great rest of the day all and God bless!
jondoeuk,
Have you even read Dr. Bosch's presentation? Read it carefully. 600 GBM patients received DCVax-L treatment. Play simple math and remind yourself how many patients receiving DCVax-L through compassionate use program. GBM Patients in compassionate use program most likely would received new batch of the vaccine from the recurrent tumor tissue as indicated in the presentation, which means the results are much better than those of p3 trial.
I haven't mentioned about of tens of patients with other types of tumors yet.
jondoeuk,
You played with the numbers the wrong way. Dr. Stupp's expertise is in the domain of chemo which will be made obsolete by DCVax-L sooner than expected.
Take a look at the type of research he is doing. Will any GBM patients try the treatment he was researching if DCVax-L is available? You should question if Dr. Stupp made the right judgement. But it seems like you were overwhelmed by the number of titles he carried over his shoulder.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00112-2/fulltext
jondoeuk,
Thanks for the reply. Your post is a distortion—it is missing crucial context and is misleading. The DCVax-L cell-based platform technology was analyzed by an independent peer review that was published in JAMA Oncology. Comments about the publication are not peer reviewed and are not part of the medical literature.
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
https://ceoworld.biz/2022/04/05/top-5-medical-journals-in-the-world-everyone-should-know-about/
NWBO - Posted by Survivor2012
Tuesday, June 13, 2023 4:24:29 AM
Ahhhaaa! Now we are talking! "FDA approval" and "DCVax" mentioned together in recent reputable (UCLA) article -- remember, MAA approval is not a prerequisite for FDA approval!! MHRA approval first -- maybe, maybe not
https://www.uclahealth.org/news/fda-approval-brain-cancer-alzheimers
jondoeuk,
Your information is incorrect about the DCVax-L cell-based platform technology. You need to seek better sources.
While I support the DCVax-L technology as an investor, I also hope for the success of NVCR’s technology, PD1 blockade, and various combo therapies.
https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171959537
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172099186
And last night Cramer RECOMMENDED.. "Stay Away From Novocure"
He is stressed out as NoCure got little to offer. & the recent highly anticipated data release confirmed that indeed IMO!
jondoeuk,
You need to stop spread misleading information to fool investors.
The future of collaboration looks dire after Merck digested Dr. Bosch's presentation. DCVax-L can be loaded with hundreds of tumor-specific antigens. DCVax-L can trigger immune memory which prevents recurrence. The clinical results from mRNA are mediocre as indicated by the Moderna SP.
NVCR investors need to take a look at how rich the NVCR CEO gets by dumping shares in the past eight years.
“These positive findings represent an important milestone in our collaboration with Moderna,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “Over the last six years, our teams have worked closely together combining our respective expertise in mRNA and immuno-oncology with a focus on improving outcomes for patients with cancer. We look forward to advancing this program into the next phase of development.” https://www.merck.com/news/moderna-and-merck-announce-mrna-4157-v940-an-investigational-personalized-mrna-cancer-vaccine-in-combination-with-keytruda-pembrolizumab-met-primary-efficacy-endpoint-in-phase-2b-keynote-94/
''Companies will initiate a Phase 3 study in patients with adjuvant melanoma in 2023, and rapidly expand to additional tumor types, including non-small cell lung cancer'' https://finance.yahoo.com/news/moderna-merck-announce-mrna-4157-150000175.html
Hard pass on that idea but thanks. God bless.
A randomised and placebo controlled trial was conducted, showing those given a placebo had a better PFS, as well as OS, which means NWBO's DCVax-L failed. As for DCVax-Direct, not a single patient responded.
Those $4b that left NVCR are going to find new place to invest. Is there a better option than NWBO? I doubt there is.
The CMO of nvcr is stepping down after all this “great” news. Yea that’s bullish. Lol
Simply put, your scared because, yes it is. Big time.
The results speak much louder than you do. NWBO will be a SOC in the near future. Possibly bought buy MRk
I’m in. Not much longer
Or.....
Close
47.00
UNCH (UNCH)
Volume
12,138,715
52 week range
46.06 - 120.03
You schall not fail to disclose … You schall not have biased relationships with biotech media mafia … $NVCR https://t.co/9LHIiVWKyu
— Michael Bigger (@biggercapital) June 7, 2023
Diminished enthusiasm for $NVCR LUNAR etc perhaps from:
— Carlo Rago, PhD (@rago_carlo) June 7, 2023
1. CIs now approved in 1L, so CI naive patients no longer exist
2. Docetaxel now considered SOC in 2L & TTFs were not stat sig better & are >>$
3. 3Qs of diminishing revenue
4. 3Qs of diminishing profit
5. Lousy adoption
Yea take to 45 and get out
Easy money from these levels! Appreciate the gift prices! God bless all!
$nvcr all you need to know about this bogus stuff. There is a lot more to peel back on this.
$nvcr all you need to know about this bogus stuff. There is a lot more to peel back on this. pic.twitter.com/7E73kTzRme
— SHM (@Persian1010) June 6, 2023
This is the process of NVCR handing the baton to NWBO to finish the race. Optune helmuts will litter the streets like discarded covid masks.
and the selloff continuing ..58.59
-23.92 -29.00% .... seems Lunar p3 a bust
Such a huge selloff just before Lunar P3 data...wow you guys must be worried, sell now if I was you....
https://www.novocure.com/novocure-announces-presentation-of-results-of-the-lunar-phase-3-clinical-trial-in-non-small-cell-lung-cancer-at-2023-american-society-of-clinical-oncology-asco-annual-meeting/
DCVax-L-treated patients had significantly prolonged OS than those treated with standard-of-care therapy (22.38?±?12.8 vs. 13.8?±?9.5 months, p?=?0.040).
#dcvax #allsolidtumors #nwbo
— Peter Davis (@peter_brit) June 6, 2023
DCVax-L-treated patients had significantly prolonged OS than those treated with standard-of-care therapy (22.38 ± 12.8 vs. 13.8 ± 9.5 months, p = 0.040).https://t.co/6MAWfT7S7x
OPEN
Last Updated: Jun 6, 2023 10:01 a.m. EDT Real time quote
$
61.09
-21.42 -25.95%
Good reason management dumping shares. .writing is on the wall
https://nwbio.com/wp-content/uploads/NWBT_ASCO_slides_06032023_FINAL.pdf
No wonder the insiders sell every share
Followers
|
28
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
552
|
Created
|
10/07/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |